Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs... Show more
a developer of antisense drugs
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MUB | 101.10 | 0.82 | +0.82% |
| iShares National Muni Bond ETF (MUB) | |||
| TYG | 38.29 | 0.09 | +0.24% |
| Tortoise Energy Infrastructure Corp | |||
| BTCZ | 2.94 | N/A | N/A |
| T-Rex 2X Inverse Bitcoin Daily Target ETF | |||
| FTF | 5.36 | N/A | N/A |
| Franklin Limited | |||
| PAYR | 52.05 | -0.64 | -1.21% |
| Federated Hermes Enhanced Income ETF (PAYR) | |||
A.I.dvisor indicates that over the last year, IONS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | -2.70% | ||
| AXON - IONS | 43% Loosely correlated | +0.70% | ||
| ARWR - IONS | 42% Loosely correlated | -1.21% | ||
| TARS - IONS | 40% Loosely correlated | +2.50% | ||
| BEAM - IONS | 37% Loosely correlated | -0.29% | ||
| PRME - IONS | 37% Loosely correlated | -1.13% | ||
More | ||||
On September 29, 2026, the Stochastic Oscillator for IONS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 44 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 73%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IONS's RSI Indicator exited the oversold zone, 19 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in 195 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
IONS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IONS as a result. In 62 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for IONS turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 35 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for IONS entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IONS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.212) is normal, around the industry mean (26.780). IONS's P/E Ratio (555.556) is considerably higher than the industry average of (43.395). Projected Growth (PEG Ratio) (4.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (8.368) is also within normal values, averaging (438.009).